Santarus and Cosmo's colitis drug meets Phase III trial's key goal

09/29/2010 | Reuters

A Phase III study found that Santarus and Cosmo Pharmaceuticals' budesonide MMX worked better than a dummy pill at putting patients with mild or moderate active ulcerative colitis in remission after eight weeks. Both 9- and 6-milligram doses of the treatment were well tolerated, the drugmakers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations